Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | PLA2G4A | P47712 | 3/20 | 0.46 |
| ▸ | CES1 | P23141 | 1/20 | 0.45 |
| ▸ | RBBP9 | O75884 | 4/20 | 0.35 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.35 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.34 |
| ▸ | CASP3 | P42574 | 2/20 | 0.34 |
| ▸ | SENP8 | Q96LD8 | 2/20 | 0.34 |
| ▸ | SENP7 | Q9BQF6 | 2/20 | 0.34 |
| ▸ | SENP6 | Q9GZR1 | 2/20 | 0.34 |
| ▸ | PLA2G7 | Q13093 | 1/20 | 0.34 |
| ▸ | HSPA9 | P38646 | 1/20 | 0.34 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.33 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.33 |
| ▸ | ACP1 | P24666 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12549113 | 0.79 | ALDH1A1 (0.50) | ALDH1A1PLA2G4ACES1RBBP9PLA2G7 | |
| SCHEMBL27690636 | 0.78 | — | — | |
| SCHEMBL28541589 | 0.77 | PLA2G4A (0.58) | ALDH1A1PLA2G4ACES1RBBP9TBXAS1 | |
| SCHEMBL13116460 | 0.76 | — | — | |
| SCHEMBL6405593 | 0.76 | — | — | |
| SCHEMBL8755650 | 0.76 | — | — | |
| SCHEMBL4809493 | 0.76 | — | — | |
| SCHEMBL3504222 | 0.76 | — | — | |
| SCHEMBL230444 | 0.76 | — | — | |
| SCHEMBL27506598 | 0.76 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8586201-B2 | Light-emitting element and iridium complex | CHIMEI INNOLUX CORPORATION (TW) | 2013-11-19 | — | — | US | disclosed |
| US-8329694-B2 | Quinoxalinones as antibacterial composition | TOYAMA CHEMICAL CO., LTD. (JP) | 2012-12-11 | — | — | US | disclosed |
| EP-2468743-A1 | Nitrogen-containing bicyclic compounds useful as antibacterial agents | Toyama Chemical Co., Ltd. (JP) | 2012-06-27 | — | — | EP | disclosed |
| US-20100168418-A1 | NOVEL NITROGENATED HETEROCYCLIC COMPOUND AND SALT THEREOF | TOYAMA CHEMICAL CO., LTD. (JP) | 2010-07-01 | — | — | US | disclosed |
| US-20100141133-A1 | LIGHT-EMITTING ELEMENT AND IRIDIUM COMPLEX | CHI MEI OPTOELECTRONICS CORP. (TW) | 2010-06-10 | — | — | US | disclosed |
| US-20100141133-A1 | LIGHT-EMITTING ELEMENT AND IRIDIUM COMPLEX | CHI MEI OPTOELECTRONICS CORP. (TW) | 2010-06-10 | — | — | US | disclosed |
| US-20070141394-A1 | LIGHT-EMITTING ELEMENT AND IRIDIUM COMPLEX | CHI MEI OPTOELECTRONICS CORP. (TW) | 2007-06-21 | — | — | US | disclosed |
| US-20070141394-A1 | LIGHT-EMITTING ELEMENT AND IRIDIUM COMPLEX | CHI MEI OPTOELECTRONICS CORP. (TW) | 2007-06-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100168418-A1 | NOVEL NITROGENATED HETEROCYCLIC COMPOUND AND SALT THEREOF | ROS1, NOX1, ARG1 | ALDH1A1 2925/4885PLA2G4A 4413/4885CES1 3320/4885 |
| US-20100141133-A1 | LIGHT-EMITTING ELEMENT AND IRIDIUM COMPLEX | AP3D1, INF2, CRY1 | ALDH1A1 2042/4885PLA2G4A 4174/4885CES1 3749/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.